P681: Effectiveness and safety of oral Tacrolimus salvage therapy for acute severe ulcerative colitis: a retrospective studyECCO’23 CopenhagenYear: 2023
Authors: Tamir-Degabli, N.(1)*;Cohen, N.A.(2);Hirsch, A.(3);Fishman, S.(2);Ron, Y.(2);Thrum, T.(2);Maharshak, N.(2);
(1)Tel Aviv Sourasky Medical Center- Tel Aviv- Israel, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel;(2)Tel Aviv Medical Center, Gastroenterology and liver diseases, Tel Aviv, Israel;(3)Tel Aviv Medical Center, Gastroenterology and liver diseases, Tel Avibv, Israel;
P682: Development of anti-ustekinumab antibodies is an independent factor associated to loss of response to ustekinumab therapy in IBD patientsECCO’23 CopenhagenYear: 2023
Authors: Roblin, X.(1)*;Nancey, S.(2);Bastide, L.(3);Veyrard, P.(3);Bischetti, G.(4);Berger, A.E.(5);Barrau, M.(6);Paul, S.(5);
(1)CHU Saint Etienne - Hospital Nord, Department of Gastroenterology and Hepatology- Inserm- CIC1408, Saint Priest en Jarez, France;(2)CHU Lyon Sud, Gastroenterelogy, Lyon, France;(3)CHU Saint Etienne, Gastroenterology, Saint Etiennne, France;(4)CHU Lyon Sud, Gastroneterology, Lyon, France;(5)CHU Saint Etienne, Immunology, Saint Etiennne, France;(6)CHU Saint Etienne, Gastronetrology, Saint Etiennne, France;
P683: Risk factors for fatigue in IBD patients.ECCO’23 CopenhagenYear: 2023
Authors: Sina, M.(1)*;Djegsi, A.(1);Pemaj, X.(1);Telaku, S.(2);Babameto, A.(1);Prifti, S.(1);
(1)University Hospital Center Mother Theresa, Internal Medicine/ Gastroenterology, Tirana, Albania;(2)UBD, Gastroenterology, Pristina, Kosovo;
P687: Durability of recaptured response to ozanimod during the True North open-label extensionECCO’23 CopenhagenYear: 2023
Authors: Dignass, A.(1)*;Regueiro, M.(2);Colombel, J.F.(3);Jain, A.(4);Canavan, J.B.(4);Wu, H.(4);Lawlor, G.(4);Osterman, M.T.(4);Vermeire, S.(5);Rubin, D.T.(6);
(1)Agaplesion Markus Hospital- Goethe University, Medicine, Frankfurt, Germany;(2)Cleveland Clinic- Cleveland, Digestive Disease and Surgery Institute, Cleveland, United States;(3)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(4)Bristol Myers Squibb, Clinical Research, Princeton, United States;(5)University of Leuven, Chronic Diseases and Metabolism, Leuven, Belgium;(6)University of Chicago, Gastroenterology, Chicago, United States;
P688: Patient preferences in medication to treat Ulcerative Colitis: a discrete choice experimentECCO’23 CopenhagenYear: 2023
Authors: Straatmijer, T.(1)*;van den Akker-van Marle, E.(2);van der Horst, D.(3);Scherpenzeel, M.(3);Duijvestein, M.(4);van der Meulen, A.(5);
(1)Initiative on Crohn and Colitis, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)LUMC, Medical decision making, Leiden, The Netherlands;(3)CCNL, Gastroenterology and hepatology, Woerden, The Netherlands;(4)Radboudumc, Gastroenterology and Hepatology, Nijmegen, The Netherlands;(5)LUMC, Gastroenterology and hepatology, Leiden, The Netherlands;
P689: Predictive transcriptional signatures associated to vedolizumab therapy response in patients with ulcerative colitis.ECCO’23 CopenhagenYear: 2023
Authors: Camba Gómez, M.(1)*;Arosa , L.(1);Calviño-Suárez, C.(2);Bastón-Rey, I.(2);Ferreiro-Iglesias, R.(2);Porto, M.(2);Nieto, L.(2);Domínguez-Muñoz, J.E.(2);Barreiro-de Acosta, M.(2);Conde-Aranda, J.(1);
(1)Health Research Institute of Santiago de Compostela IDIS, Molecular and Cellular Gastroenterology, Santiago de Compostela, Spain;(2)University Hospital of Santiago de Compostela, Department of Gastroenterology and Hepatology, Santiago de Compostela, Spain;
P690: Prolonged benefit of filgotinib in patients with Ulcerative Colitis in SELECTIONECCO’23 CopenhagenYear: 2023
Authors: Laharie, D.(1)*;Sturm, A.(2);Kobayashi, T.(3);Matsumoto, T.(4);Oortwijn, A.(5);Jamoul , C.(6);Faes, M.(6);de Haas, A.(7);Vermeire , S.(8);
(1)Hospital Haut-Leveque, Department of Gastroenterology and Hepatology, Pessac, France;(2)DRK Kliniken Berlin Westend, Department of Internal Medicine and Gastroenterology, Berlin, Germany;(3)Center for Advanced IBD Research and Treatment, Kitasato University- Kitasato Institute Hospital, Toyko, Japan;(4)Iwate Medical University, Division of Gastroenterology- Department of Medicine, Morioka, Japan;(5)Galapagos NV, Medical Affairs Department, Leiden, The Netherlands;(6)Galapagos NV, Biostatistics Department, Mechelen, Belgium;(7)Galapagos NV, Clinical Development Department, Leiden, The Netherlands;(8)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
P691: Disparate care: rates of treat to target among patients with inflammatory bowel diseaseECCO’23 CopenhagenYear: 2023
Authors: Haydek, J.(1);Oonk, A.(1);Cheng, D.(1);Ahmed, W.(1);Click, B.(1);Fennimore, B.(1);Gerich, M.(1);Hou, J.(2);Scott, F.(1)*;
(1)University of Colorado, Crohn's and Colitis Center, Aurora, United States;(2)Baylor College of Medicine, Gastroenterology and Hepatology, Houston, United States;
P693: Italian real-life study evaluating the long-term effectiveness of vedolizumab for the treatment of Inflammatory Bowel Disease- An IG-IBD studyECCO’23 CopenhagenYear: 2023
Authors: Pugliese, D.(1);Privitera, G.(2)*;Armuzzi, A.(3);
(1)Fondazione Policlinico Agostino Gemelli IRCCS, CEMAD- IBD CENTER- Unità Operativa Complessa di Medicina Interna e Gastroenterologia- Dipartimento di Scienze Mediche e Chirurgiche, Rome, Italy;(2)Università Cattolica del Sacro Cuore, Dipartimento di Medicina e Chirurgia Traslazionale, Roma, Italy;(3)IRCCS Humanitas Research Hospital, IBD Center, Rozzano, Italy;IG-IBD LIVE Studygroup
P694: Long-term monitoring of post-surgical recurrence in Crohn's disease using a strategy based on the periodic determination of fecal calprotectin in patients without early postoperative recurrenceECCO’23 CopenhagenYear: 2023
Authors: Mañosa CiriaPhD, M.(1,2)*;Oller, B.(1);Garcia-Planella, E.(3);Guardiola, J.(4);Cañete, F.(1,2);Gonzalez Muñoza, C.(3);Camps, B.(4);Calafat, M.(1,2);Domènech, E.(2,5);
(1)Hospital Universitari Germans Trias I Pujol, Gastroenterology, Badalona, Spain;(2)Ciberehd, Ciberehd, Madrid, Spain;(3)Hospital de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain;(4)Hospital de Bellvitge, Gastroenterology, L'Hospitalet de LLobregat, Spain;(5)Hospital Universitari Germain Trias i Pujol, Gastroenterology, Badalona, Spain;
P695: Effectiveness and Safety of Combination Biologic or Small Molecule Therapy in Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: McShane, C.(1)*;Varley, R.(2);Fennessy, A.(3);Campion, J.(4);Ring, E.(5);Kelly, O.(5);Slattery, E.(4);Doherty, G.(6);McCarthy, J.(2);Kevans, D.(7);
(1)St James's Hospital, Department of Gastroenterology, Dublin, Ireland;(2)Mercy University Hospital, Department of Gastroenterology, Cork, Ireland;(3)St Vincent's University Hospital, Department of Gastroenterology and Colorectal Disease, Dublin, Ireland;(4)Galway University Hospital, Department of Gastroenterology, Galway, Ireland;(5)Connolly Hospital, Department of Gastroenterology, Dublin, Ireland;(6)Department of Gastroenterology and Colorectal Disease, Department of Gastroenterology, Dublin, Ireland;(7)St. James's Hospital, Department of Gastroenterology, Dublin, Ireland;INITIative Network
P696: Design and rationale for the multicentre, randomised, controlled VERDICT trial to determine the optimal treatment target in patients with ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Jairath, V.(1,2,3)*;Zou, G.(2,3,4);Radulescu, G.(3);Sigler, J.(3);Mcfarlane, S.C.(3);Adsul, S.(5);Freire, M.(5);Peyrin-Biroulet, L.(6);Colombel, J.F.(7);Moran, G.W.(8,9);Sebastian, S.(10,11);Travis, S.(12);Vermeire, S.(13);Sandborn, W.J.(14);D'Haens, G.R.(15); Feagan, B.G.(1,2,3);
(1)University of Western Ontario, Department of Medicine- Division of Gastroenterology, London, Canada;(2)University of Western Ontario, Department of Epidemiology and Biostatistics, London, Canada;(3)Alimentiv Inc., Medical Research and Development, London, Canada;(4)University of Western Ontario, Robarts Research Institute- Schulich School of Medicine and Dentistry, London, Canada;(5)Takeda Pharmaceuticals, Medical, Cambridge, United States;(6)Inserm NGERE U1256- University Hospital of Nancy- University of Lorraine, Department of Gastroenterology, Vandoeuvre-lès-Nancy, France;(7)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(8)University of Nottingham, Nottingham Digestive Diseases Biomedical Research Centre, Nottingham, United Kingdom;(9)Nottingham University Hospitals NHS Trust, NIHR Nottingham Biomedical Research Centre, Nottingham, United Kingdom;(10)Hull Royal Infirmary, Hull and East Yorkshire NHS Trust & Hull and York Medical School, Hull, United Kingdom;(11)Hull York Medical School, School of Health & Life Sciences, Hull, United Kingdom;(12)University of Oxford, Kennedy Institute and Biomedical Research Centre, Oxford, United Kingdom;(13)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(14)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(15)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;on behalf of the VERDICT Study Group
P697: De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice.ECCO’23 CopenhagenYear: 2023
Authors: Arenas, A.(1,2,3)*;Moreta, M.J.(4);Ordás, I.(1,4);Fernández-Clotet, A.(1,4);Caballol, B.(1,4);Gallego, M.(1,4);Vara, A.(1,4);Barastegui, R.(1,4);Giner, A.(1,4);Prieto, C.(1,4);Masamunt, M.C.(1,4);Ricart, E.(1,4);
(1)Hospital Clínic, Inflammatory Bowel Disease Unit, Barcelona, Spain;(2)Complejo Asistencial Dr. Sótero del Río, Unidad de Gastroenterología, Santiago, Chile;(3)Facultad de Medicina Clínica Alemana-Universidad del Desarrollo, Gastroenterología, Santiago, Chile;(4)Hospital Clínic, Gastroenterology, Barcelona, Spain;
P698: Role of an exclusion diet (reduced disaccharides, saturated fats, emulsifiers, red and ultraprocessed meats) in maintaining the remission of chronic inflammatory bowel diseases in adultsECCO’23 CopenhagenYear: 2023
Authors: Preda, C.M.(1)*;Istratescu, D.(2);Manuc, T.(2);Nitescu, M.(3);Louis, E.(4);Manuc, M.(2);Stroie, T.(2);Diculescu, M.(2);
(1)Clinical Institute Fundeni, Department of Gastroenterology and Hepatology, Bucharest, Romania;(2)Clinical Fundeni Institute, Department of Gastroenterology and Hepatology, Bucharest, Romania;(3)UMF „Carol Davila” National Institute for Infectious Diseases Prof. Dr. MateiBals-, Department of Infectious Diseases, Bucharest, Romania;(4)CHU de Liege, Department of Gastroenterology, Liege, Belgium;
P699: Ustekinumab therapy after biologic failure in patients with Crohn's Disease – A real-world single centre experienceECCO’23 CopenhagenYear: 2023
Authors: Majumder, S.(1,2,3)*;Bazarova, A.(4);Lorenzo Parigi, T.(1,3); Love , M.(5);Davis , J.(3);Ghosh, S.(6); Iacucci , M.(1,3,7);N. Shivaji, U.(1,3,7);
(1)University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom;(2)India Institute- University of Birmingham, Fellowship, Birmingham, United Kingdom;(3)University Hospitals Birmingham NHS Foundation Trust, Gastroenterology, Birmingham, United Kingdom;(4)Institute for Biological Physics University of Cologne, Biological Physics, Cologne, Germany;(5)University Hospitals Birmingham NHS Foundation Trust, Gastroenterology, Gastroenterology, United Kingdom;(6)College of Medicine and Health- University College Cork, APC Microbiome, Cork, Ireland;(7)National Institute for Health Research NIHR Birmingham Biomedical Research Centre- University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom;
P700: Perceptions towards established and emerging dietary therapies for Crohn's disease management among the adult patients: results from a questionnaire surveyECCO’23 CopenhagenYear: 2023
Authors: Jatkowska, A.(1);White, B.(1);Jaskolski, P.(1);Brownson, E.(2);Clowe, J.(2);Seenan, J.P.(2);Gerasimidis, K.(1)*;MacDonald, J.(2);
(1)University of Glasgow, Human Nutrition, Glasgow, United Kingdom;(2)Queen Elizabeth University Hospital, Department of Gastroenterology, Glasgow, United Kingdom;
P701: A time-to-event model relating infliximab trough concentrations to the risk of relapse after extending the infusion intervalECCO’23 CopenhagenYear: 2023
Authors: Kantasiripitak, W.(1);Outtier, A.(2,3);Thomas, D.(1);Sabino, J.(2,3);Vermeire, S.(2,3);Ferrante, M.(2,3);Dreesen, E.(1)*;
(1)University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)University of Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;
P702: Clinical and biomarker remission is maintained after switch from monthly dosed intravenous to subcutaneous maintenance treatment with vedolizumab in Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Spela, P.(1)*;Hanžel, J.(2);Smrekar, N.(2);Koželj, M.(2);Drobne, D.(2);Kurent, T.(2);Štabuc, B.(2);Novak, G.(2);
(1)UKC Ljubljana, Departement for gastroenterology and hepatology, Ljubljana, Slovenia;(2)University Medical Centre Ljubljana, Departement for gastroentrerology and hepatology, Ljubljana, Slovenia;
